泽璟制药布局A+H：65岁外籍董事长盛泽林博士学历，去年薪酬289万元

Core Viewpoint - Zai Jian Pharmaceutical plans to issue overseas listed shares (H shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international brand recognition and competitiveness [2] Group 1: Company Overview - Zai Jian Pharmaceutical was established in 2009, with a registered capital of 265 million yuan, focusing on the research, production, and sales of chemical and biological new drugs [2] - The company is currently led by Sheng Zelin, who serves as both Chairman and General Manager [4] Group 2: Financial Performance - For the first three quarters of 2025, Zai Jian Pharmaceutical reported a revenue of 593 million yuan, representing a year-on-year increase of 54.49% [2][3] - The net profit attributable to shareholders was -93.42 million yuan, slightly improved from -97.90 million yuan in the same period last year [2][3] - The total profit for the reporting period was -209.05 million yuan, with a cash flow from operating activities of -16.73 million yuan [3]